Who are CHF5633's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symdeko (Copackaged), Ivacaftor/Ataluren, Elexacaftor / Ivacaftor / Tezacaftor, IVA, Ivacaftor+lumacaftor, Initiation of CFTR Modulator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf5633.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CHF5633 — Competitive Intelligence Brief

CHF5633 (CHF5633) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR corrector. Area: Respiratory.

phase 2 CFTR corrector CFTR Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

CHF5633 (CHF5633) — Chiesi Farmaceutici S.p.A.. CHF5633 is a small molecule in development for the treatment of cystic fibrosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CHF5633 TARGET	CHF5633	Chiesi Farmaceutici S.p.A.	phase 2	CFTR corrector	CFTR
Symdeko (Copackaged)	TEZACAFTOR	Vertex Pharms	marketed		CFTR	2018-01-01
Ivacaftor/Ataluren	Ivacaftor/Ataluren	University of Alabama at Birmingham	marketed	CFTR modulator combination	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)
Elexacaftor / Ivacaftor / Tezacaftor	Elexacaftor / Ivacaftor / Tezacaftor	Nottingham University Hospitals NHS Trust	marketed	CFTR modulator combination (correctors + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
IVA	IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor+lumacaftor	Ivacaftor+lumacaftor	Assistance Publique - Hôpitaux de Paris	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Initiation of CFTR Modulator	Initiation of CFTR Modulator	Children's Hospital Medical Center, Cincinnati	marketed	CFTR modulator	CFTR (cystic fibrosis transmembrane conductance regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-06 — Symdeko (Copackaged) · 8354427 · US
2026-12-28 — Symdeko (Copackaged) · 9931334 · US
2026-12-28 — Symdeko (Copackaged) · 9670163 · US
2026-12-28 — Symdeko (Copackaged) · 8754224 · US
2026-12-28 — Symdeko (Copackaged) · 8410274 · US
2027-04-09 — Symdeko (Copackaged) · 10239867 · US
2027-04-09 — Symdeko (Copackaged) · 9974781 · US
2027-04-09 — Symdeko (Copackaged) · 11639347 · US
2027-04-09 — Symdeko (Copackaged) · 10022352 · US
2027-05-01 — Symdeko (Copackaged) · 8598181 · US
2027-05-01 — Symdeko (Copackaged) · 7645789 · US
2027-05-01 — Symdeko (Copackaged) · 8623905 · US
2027-05-20 — Symdeko (Copackaged) · 7495103 · US
2027-06-03 — Symdeko (Copackaged) · 7776905 · US
2027-08-05 — Symdeko (Copackaged) · 8324242 · US
2027-11-12 — Symdeko (Copackaged) · 8415387 · US
2029-08-13 — Symdeko (Copackaged) · 11564916 · US
2029-08-13 — Symdeko (Copackaged) · 10646481 · US
2031-03-25 — Symdeko (Copackaged) · 10081621 · US
2031-03-25 — Symdeko (Copackaged) · 11578062 · US
2033-07-15 — Symdeko (Copackaged) · 10058546 · US
2033-07-15 — Symdeko (Copackaged) · 9012496 · US
2035-04-14 — Symdeko (Copackaged) · 10206877 · US

Sponsor landscape (CFTR corrector class)

Vertex Pharmaceuticals Incorporated · 3 drugs in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
Renovion, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF5633 — Competitive Intelligence Brief. https://druglandscape.com/ci/chf5633. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab